At the molecular level, 5-amino-1MQ functions as a competitive inhibitor of NNMT, demonstrating remarkable potency with an IC of 1.2 0.1 M under standard assay conditions (50 M SAM, 100 M nicotinic acid). This represents a dramatic 10-fold improvement over the parent compound 1-methylquinolinium, achieved through strategic amino group substitution that enhances binding affinity to the NNMT active site. The compound's mechanism centers on preventing the methylation of nicotinamide to 1-methylnicotinamide (1-MNA), thereby preserving nicotinamide for recycling back to NAD+ through the salvage pathway. This intervention effectively blocks what researchers have termed the "NNMT metabolic drain" a process that simultaneously depletes NAD+ precursors and consumes cellular methylation capacity
For most users, reputable compounding pharmacies produce formulations that are bioequivalent to brand products
In common use, though, people say GLP-1 to mean FDA-approved incretin drugs for weight/diabetes, and peptide therapy to mean other wellness-oriented peptides used off-label for recovery, sleep, and healthy aging
For related cellular wellness support, learn more about NAD+ IV therapy
If you are looking for a Certificate Of Analysis, please email [email protected] to have it sent to you
MCAS, liver function, and a few other possibilities deserve a workup
